S&P 500   4,402.20
DOW   34,440.88
QQQ   364.54
3 ETFs for the Conservative Investor to Buy and Hold
How is This "Hidden Gem" Thriving in a Turbulent Market? (Ad)
Stock market today: World shares track Wall Street's slump after Fed says rates may stay high in '24
Are These Consumer Staples Too Cheap for Investors To Ignore?
Is Gold Really Boring? (Ad)
A small venture capital player becomes a symbol in the fight over corporate diversity policies
Markets Are Loving These Stocks 'Firing On All Cylinders'
Is Gold Really Boring? (Ad)
Etsy Gets an Upgrade and $100 Target...Is the Bottom Finally In?
'Enough Venom to Fill a Martini Glass and Kill 5 People': An Amazon Driver Was Bitten By a Rattlesnake on the Job in Florida
S&P 500   4,402.20
DOW   34,440.88
QQQ   364.54
3 ETFs for the Conservative Investor to Buy and Hold
How is This "Hidden Gem" Thriving in a Turbulent Market? (Ad)
Stock market today: World shares track Wall Street's slump after Fed says rates may stay high in '24
Are These Consumer Staples Too Cheap for Investors To Ignore?
Is Gold Really Boring? (Ad)
A small venture capital player becomes a symbol in the fight over corporate diversity policies
Markets Are Loving These Stocks 'Firing On All Cylinders'
Is Gold Really Boring? (Ad)
Etsy Gets an Upgrade and $100 Target...Is the Bottom Finally In?
'Enough Venom to Fill a Martini Glass and Kill 5 People': An Amazon Driver Was Bitten By a Rattlesnake on the Job in Florida
S&P 500   4,402.20
DOW   34,440.88
QQQ   364.54
3 ETFs for the Conservative Investor to Buy and Hold
How is This "Hidden Gem" Thriving in a Turbulent Market? (Ad)
Stock market today: World shares track Wall Street's slump after Fed says rates may stay high in '24
Are These Consumer Staples Too Cheap for Investors To Ignore?
Is Gold Really Boring? (Ad)
A small venture capital player becomes a symbol in the fight over corporate diversity policies
Markets Are Loving These Stocks 'Firing On All Cylinders'
Is Gold Really Boring? (Ad)
Etsy Gets an Upgrade and $100 Target...Is the Bottom Finally In?
'Enough Venom to Fill a Martini Glass and Kill 5 People': An Amazon Driver Was Bitten By a Rattlesnake on the Job in Florida
S&P 500   4,402.20
DOW   34,440.88
QQQ   364.54
3 ETFs for the Conservative Investor to Buy and Hold
How is This "Hidden Gem" Thriving in a Turbulent Market? (Ad)
Stock market today: World shares track Wall Street's slump after Fed says rates may stay high in '24
Are These Consumer Staples Too Cheap for Investors To Ignore?
Is Gold Really Boring? (Ad)
A small venture capital player becomes a symbol in the fight over corporate diversity policies
Markets Are Loving These Stocks 'Firing On All Cylinders'
Is Gold Really Boring? (Ad)
Etsy Gets an Upgrade and $100 Target...Is the Bottom Finally In?
'Enough Venom to Fill a Martini Glass and Kill 5 People': An Amazon Driver Was Bitten By a Rattlesnake on the Job in Florida
NASDAQ:BMEA

Biomea Fusion (BMEA) Stock Forecast, Price & News

$13.86
-1.14 (-7.60%)
(As of 09/20/2023 ET)
Compare
Today's Range
$13.83
$14.92
50-Day Range
$13.86
$23.02
52-Week Range
$6.04
$43.69
Volume
433,235 shs
Average Volume
682,512 shs
Market Capitalization
$493.86 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$43.88

Biomea Fusion MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.89 Rating Score
Upside/​Downside
216.6% Upside
$43.88 Price Target
Short Interest
Bearish
27.46% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.87mentions of Biomea Fusion in the last 14 days
Based on 3 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($3.42) to ($3.76) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.82 out of 5 stars

Medical Sector

773rd out of 962 stocks

Pharmaceutical Preparations Industry

359th out of 448 stocks


BMEA stock logo

About Biomea Fusion (NASDAQ:BMEA) Stock

Biomea Fusion, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, an orally bioavailable, potent, and selective covalent inhibitor of menin for treating patients with liquid and solid tumors and type 2 diabetes. Biomea Fusion, Inc. was incorporated in 2017 and is headquartered in Redwood City, California.

BMEA Price History

BMEA Stock News Headlines

Is Gold Really Boring?
Many investors perceive gold as a "boring" investment. But according to MoneyWeek, that's a good thing. Gold helps investors sleep soundly as it preserves wealth and creates a hedge against inflation. Today, there's a unique way to invest in gold, with real advantages over coins and mining stocks.
H.C. Wainwright Remains a Buy on Biomea Fusion (BMEA)
14 Analysts Have This to Say About Biomea Fusion
How is This "Hidden Gem" Thriving in a Turbulent Market?
While Wall Street flounders and giants like Amazon & Microsoft lay off thousands... One overlooked company has been quietly achieving over 400% growth. How? By buying, building, and scaling a portfolio of promising brands in high-margin, recession-resistant verticals.
Biomea Fusion (BMEA) Gets a Buy from H.C. Wainwright
Why Biomea Fusion Stock Is Falling Today?
What 18 Analyst Ratings Have To Say About Biomea Fusion
Piper Sandler Reaffirms Their Buy Rating on Biomea Fusion (BMEA)
Biomea Fusion Stock Is Trading Higher Today - Here's Why
Did You Pick These Biotech High-Flyers Before They Hit New Highs?
See More Headlines
Receive BMEA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Biomea Fusion and its competitors with MarketBeat's FREE daily newsletter.

BMEA Company Calendar

Last Earnings
7/31/2023
Today
9/21/2023
Next Earnings (Estimated)
11/06/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:BMEA
Fax
N/A
Employees
94
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$43.88
High Stock Price Forecast
$60.00
Low Stock Price Forecast
$22.00
Forecasted Upside/Downside
+216.6%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.89
Research Coverage
9 Analysts

Profitability

Net Income
$-81,830,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$3.69 per share

Miscellaneous

Free Float
26,271,000
Market Cap
$493.86 million
Optionable
Not Optionable
Beta
-1.27
Investing Strategies To Help Grow Your Retirement Income Cover

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Key Executives

  • Mr. Thomas Andrew Butler (Age 42)
    Co-Founder, Chairman & CEO
    Comp: $921.14k
  • Mr. Ramses M. ErdtmannMr. Ramses M. Erdtmann (Age 60)
    Co-Founder, Pres, COO & Director
    Comp: $659.53k
  • Mr. Franco  ValleMr. Franco Valle (Age 42)
    CFO & Principal Accounting Officer
    Comp: $651.77k
  • Mr. Heow Tan (Age 64)
    Chief Technology & Quality Officer
  • Ms. Naomi Cretcher
    Chief People Officer
  • Dr. Thorsten Kirschberg Ph.D. (Age 53)
    Exec. VP of Chemistry
  • Dr. Stephan Morris M.D.
    Chief Devel. Officer
  • Mr. Ravi Upasani
    Exec. VP of Intellectual Property
  • Dr. Juan Pablo Frias M.D.
    Chief Medical Officer & Member of Scientific Advisory Board













BMEA Stock - Frequently Asked Questions

Should I buy or sell Biomea Fusion stock right now?

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Biomea Fusion in the last twelve months. There are currently 1 hold rating and 8 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" BMEA shares.
View BMEA analyst ratings
or view top-rated stocks.

What is Biomea Fusion's stock price forecast for 2023?

9 Wall Street analysts have issued 1 year price targets for Biomea Fusion's shares. Their BMEA share price forecasts range from $22.00 to $60.00. On average, they expect the company's stock price to reach $43.88 in the next year. This suggests a possible upside of 216.6% from the stock's current price.
View analysts price targets for BMEA
or view top-rated stocks among Wall Street analysts.

How have BMEA shares performed in 2023?

Biomea Fusion's stock was trading at $8.43 at the beginning of the year. Since then, BMEA stock has increased by 64.4% and is now trading at $13.86.
View the best growth stocks for 2023 here
.

When is Biomea Fusion's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, November 6th 2023.
View our BMEA earnings forecast
.

How were Biomea Fusion's earnings last quarter?

Biomea Fusion, Inc. (NASDAQ:BMEA) issued its quarterly earnings results on Monday, July, 31st. The company reported ($0.70) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.86) by $0.16.

What ETF holds Biomea Fusion's stock ?

Invesco Dorsey Wright Healthcare Momentum ETF holds 113,300 shares of BMEA stock, representing 1.44% of its portfolio.

When did Biomea Fusion IPO?

(BMEA) raised $120 million in an initial public offering (IPO) on Friday, April 16th 2021. The company issued 7,500,000 shares at a price of $15.00-$17.00 per share. J.P. Morgan, Jefferies and Piper Sandler served as the underwriters for the IPO.

What is Biomea Fusion's stock symbol?

Biomea Fusion trades on the NASDAQ under the ticker symbol "BMEA."

Who are Biomea Fusion's major shareholders?

Biomea Fusion's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (5.50%), State Street Corp (4.40%), Driehaus Capital Management LLC (3.31%), Rock Springs Capital Management LP (2.35%), Perceptive Advisors LLC (2.01%) and Geode Capital Management LLC (1.21%). Insiders that own company stock include A2a Pharmaceuticals, Inc, Bihua Chen, Franco Valle, Global Healthcare Ma Cormorant, Michael JM Hitchcock and Rainer M Erdtmann.
View institutional ownership trends
.

How do I buy shares of Biomea Fusion?

Shares of BMEA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Biomea Fusion's stock price today?

One share of BMEA stock can currently be purchased for approximately $13.86.

How much money does Biomea Fusion make?

Biomea Fusion (NASDAQ:BMEA) has a market capitalization of $493.86 million. The company earns $-81,830,000.00 in net income (profit) each year or ($3.32) on an earnings per share basis.

How can I contact Biomea Fusion?

The official website for the company is www.biomeafusion.com. The company can be reached via phone at 650-980-9099 or via email at vsandwick@biomeafusion.com.

This page (NASDAQ:BMEA) was last updated on 9/21/2023 by MarketBeat.com Staff

My Account -